By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



4560 Horton Street

Emeryville  California  94608-2916  U.S.A.
Phone: 510-655-8730 Fax: n/a


Grifols Diagnostic division provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. We also explore development of molecular testing and other novel technologies with the potential to further improve treatment outcomes and laboratory efficiency.

Our broad product portfolio is designed to deliver fast and accurate information for healthcare providers working to select the safest and most effective treatments for patients. As a leader in transfusion medicine, Grifols is proud that blood banks and transfusion centers around the world trust our automated laboratory systems, broad test menu, and expert service and support to address their full range of blood screening and pre-transfusion testing needs.

Key Statistics

Ownership: Public

Web Site: Grifols
Employees: 800
Symbol: GRFS


Company News
FDA Approves Use Of The Procleix Zika Virus Assay From Hologic (HOLX) And Grifols (GRFS) To Screen The U.S. Blood Supply Under An IND Study Protocol 6/20/2016 6:40:00 AM
Grifols (GRFS) To Install The Kiro Oncology Robot At Smilow Cancer Hospital 6/10/2016 8:50:11 AM
Grifols (GRFS) Coughs Up $50 Million for a 20% Stake in Singulex 5/31/2016 7:54:31 AM
Grifols (GRFS) 2015 Annual Report On Form 20-F Filed With The SEC On April 5, 2016 4/5/2016 6:35:39 AM
Lurie Children’s Hospital Selects Grifols (GRFS) KIRO Robot To Increase Precision, Safety, And Compliance Of Pediatric IV Chemotherapy Handling And Compounding 3/23/2016 9:58:40 AM
Grifols (GRFS) 2014 Annual Report On Form 20-F Filed With The SEC On April 1, 2015 4/1/2015 6:05:09 AM
Plasma Medication Manufacturer Grifols Opens State-Of-The-Art Facility In North Carolina, 200 New Jobs On The Horizon 6/17/2014 11:13:20 AM
Grifols Completes Patient Enrollment In Its Phase2/3 Psoriasis Trial; Final Results Are Expected In Q1 2015 6/17/2014 10:50:26 AM
TiGenix: Appoints Gri-Cel CEO Dirk Buscher And COO Jose Terencio To Board Of Directors Following Strategic Investment By Grifols 12/5/2013 9:36:31 AM
TiGenix Completes EUR 12 Million Capital Increase With Strategic Investor Grifols 11/22/2013 9:28:33 AM